| Quarterly Financials | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 1 | 6 | 5 | 5 | 5 | 5 | 7 | 12 |
| Expenses | 0 | 1 | 1 | 9 | 2 | 2 | 1 | 3 | 11 | 8 | 8 | 8 | 9 | 12 | 14 |
| EBITDA | -0 | -1 | -1 | -9 | -1 | -1 | -1 | -2 | -6 | -4 | -2 | -3 | -4 | -5 | -2 |
| Operating Profit % | 0 % | 0 % | 0 % | 0 % | 0 % | 0 % | 0 % | -12,200 % | -96 % | -74 % | -46 % | -62 % | -82 % | -81 % | -62 % |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit Before Tax | -0 | -1 | -1 | -9 | -1 | -1 | -1 | -2 | -7 | -4 | -3 | -4 | -5 | -7 | -4 |
| Tax | 0 | 0 | 0 | -2 | 0 | 0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -2 | -1 |
| Net Profit | -0 | -1 | -1 | -6 | -1 | -1 | -1 | -1 | -6 | -3 | -2 | -3 | -5 | -5 | -3 |
| EPS in ₹ | 0.00 | -0.05 | -0.54 | -4.76 | -0.61 | -0.61 | -0.24 | -0.54 | -2.82 | -0.76 | -0.73 | -0.55 | -1.11 | -1.39 | -0.70 |
Pharmaids Pharmaceuticals
Pharmaids Pharmaceuticals
49.00
+2.01
(4.28%)
Key Fundamentals
Market Cap
172.79 Cr
EPS
-3.05
PE Ratio
-10.61
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
84.97
52 Week Low
42.00
PB Ratio
3.19
Debt to Equity
0.36
Sector
Pharmaceuticals Actual
Company News
View All News
Pharmaids Pharmaceuticals Reports Wider Losses in Q2 FY26, Exits Partnership with Anugraha Chemicals8 days ago
Pharmaids Pharmaceuticals Limited reported a standalone net loss of Rs 165.23 lakhs for the quarter ended September 30, 2025, compared to a loss of Rs 100.66 lakhs in the same period last year. Revenue from operations increased significantly to Rs 596.55 lakhs from Rs 83.40 lakhs year-over-year. For the half-year period, the company's standalone loss widened to Rs 601.53 lakhs versus Rs 263.00 lakhs in the previous year, while revenue grew to Rs 708.08 lakhs from Rs 100.05 lakhs. On a consolidated basis, the company reported a net loss of Rs 252.83 lakhs for the quarter and Rs 780.61 lakhs for the half-year. The company completed its exit from partnership firm Anugraha Chemicals by divesting its entire 66.5% stake, receiving consideration of Rs 1,050 lakhs. Pharmaids operates in the Contract Research and Manufacturing Services segment. The Board of Directors approved these unaudited financial results in their meeting held on November 11, 2025.
Pharmaids Pharmaceuticals Reclassifies 12 Promoters to Public Category Following Completed Open Offer
Sep 24, 2025
Sep 24, 2025Pharmaids Pharmaceuticals Limited has reclassified 12 individuals from the Promoter/Promoter Group category to the Public category following the completion of an open offer by Dr. Shankarappa Nagaraja Vinaya Babu and Tumkur Trade Center Private Limited on September 23, 2025. The reclassified individuals collectively held 5.10% shareholding, with Sadhanala Venkata Rao being the largest at 4.32%. The reclassified promoters confirmed they do not hold more than 10% voting rights, do not exercise control over company affairs, have no special rights, and will not be represented on the Board for three years. Following the open offer completion, Dr. Shankarappa Nagaraja Vinaya Babu and Tumkur Trade Center Private Limited are now classified as the company's promoters. The company confirmed compliance with minimum public shareholding requirements and has no outstanding dues to regulatory authorities.
Pharmaids Pharmaceuticals Sells Entire 66.50% Stake in Anugraha Chemicals for Rs 6.65 LakhSep 18, 2025
Sep 18, 2025Pharmaids Pharmaceuticals Limited completed the sale of its entire 66.50% partnership stake in Anugraha Chemicals to Mrs. Sneha Hadimani for Rs 6,65,000 on September 18, 2025. The divestment was approved by shareholders through postal ballot on August 14, 2025, and the Board of Directors on July 4, 2025. Following the transaction, Anugraha Chemicals ceased to be a material subsidiary of Pharmaids Pharmaceuticals. The company also executed a Termination Agreement to end the Investment Agreement dated January 25, 2023. Anugraha Chemicals contributed Rs 13,40,05,450 (68.91%) to consolidated revenue and Rs 3,74,15,092 (6.80%) to consolidated net worth as of March 31, 2025. The buyer is not related to the promoter group, and the transaction does not constitute a related party transaction. Additional amounts for loans, interest adjustments and other dues will be received separately.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,784.10 | #1 4,28,065.35 | 40.27 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 74.53 | |
6,454.00 | 1,71,333.42 | 69.17 | 9,712.00 | 18.67 | 2,191 | 35.10 | 46.81 | |
3,731.40 | 1,26,287.53 | 59.99 | 11,539.40 | 6.99 | 1,911 | 30.46 | 56.17 | |
1,526.80 | 1,23,327.89 | 22.52 | 28,409.50 | 7.12 | 5,291 | 3.71 | 47.29 | |
1,250.20 | 1,04,343.41 | #1 18.09 | 33,741.20 | 16.73 | 5,725 | -0.38 | 54.25 | |
930.20 | 93,599.89 | 18.57 | 23,511.00 | 18.55 | 4,615 | 34.60 | 33.90 | |
2,025.40 | 92,511.06 | 21.51 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 57.78 | |
2,223.10 | 91,760.34 | 51.75 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 29.21 | |
1,235.80 | 71,775.46 | 21.23 | 32,345.60 | 9.43 | 3,484 | 3.81 | 74.03 | |
5,724.00 | 68,439.01 | 28.33 | 13,458.30 | 3.70 | 2,216 | 10.98 | 64.07 |
Growth Rate
Revenue Growth
22.50 %
Net Income Growth
14.41 %
Cash Flow Change
-31.73 %
ROE
46.07 %
ROCE
-5.39 %
EBITDA Margin (Avg.)
-10.09 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 11 | 25 | 91 | 120 |
| Fixed Assets | 0 | 0 | 63 | 77 |
| Current Assets | 3 | 18 | 14 | 22 |
| Capital Work in Progress | 0 | 2 | 7 | 5 |
| Investments | 0 | 3 | 0 | 0 |
| Other Assets | 11 | 19 | 21 | 39 |
| Total Liabilities | 11 | 25 | 91 | 120 |
| Current Liabilities | 2 | 2 | 12 | 29 |
| Non Current Liabilities | 0 | 0 | 9 | 36 |
| Total Equity | 9 | 23 | 71 | 55 |
| Reserve & Surplus | -2 | 1 | 37 | 24 |
| Share Capital | 10 | 21 | 35 | 35 |
Cash Flow
| Cash Flow | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 0 | 12 | -8 | -3 |
| Investing Activities | 1 | -5 | -75 | -12 |
| Operating Activities | -0 | -4 | -11 | -14 |
| Financing Activities | 0 | 21 | 78 | 23 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Jan 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Apr 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 65.81 % | 65.80 % | 65.65 % | 55.56 % | 35.44 % | 20.70 % | 21.08 % | 16.54 % | 16.45 % | 9.95 % | 9.94 % | 9.70 % | 9.25 % | 5.64 % | 5.64 % | 5.56 % | 5.19 % | 5.22 % | 5.22 % | 5.14 % | 32.99 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 33.44 % | 33.19 % | 33.70 % | 43.47 % | 63.98 % | 78.72 % | 74.07 % | 69.78 % | 69.87 % | 81.71 % | 81.27 % | 81.93 % | 60.78 % | 41.06 % | 41.06 % | 41.14 % | 41.03 % | 36.42 % | 36.59 % | 36.35 % | 47.02 % |
| Others | 0.74 % | 1.01 % | 0.65 % | 0.97 % | 0.58 % | 0.57 % | 4.84 % | 13.68 % | 13.68 % | 8.34 % | 8.79 % | 8.37 % | 29.96 % | 53.30 % | 53.30 % | 53.29 % | 53.78 % | 58.37 % | 58.20 % | 58.51 % | 19.99 % |
| No of Share Holders | 5,861 | 7,192 | 7,331 | 8,314 | 9,620 | 9,495 | 9,193 | 8,862 | 8,196 | 7,761 | 7,476 | 7,393 | 7,281 | 7,554 | 7,567 | 7,594 | 8,050 | 8,349 | 8,220 | 8,026 | 8,027 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 31 Dec 2022 |  Extraordinary General Meeting | NA | 31 Dec 2022 | 18.95 | 28.00 |
| 31 Jan 2024 | Extraordinary General Meeting | NA | 31 Jan 2024 | 62.10 | 61.02 |
| 25 Sept 2024 |  Annual General Meeting | NA | 25 Sept 2024 | 45.34 | 39.89 |
| 13 Nov 2024 |  Quarterly Result Announcement | NA | 13 Nov 2024 | 68.56 | 83.30 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 73.59 | 68.30 |
| 23 May 2025 | Quarterly Result Announcement | NA | 23 May 2025 | 67.93 | 67.72 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 63.22 | 63.49 |
| 21 Aug 2025 | Quarterly Result Announcement | NA | 21 Aug 2025 | 62.15 | 62.15 |
| 23 Sept 2025 | Annual General Meeting | NA | 23 Sept 2025 | 59.54 | 56.95 |
| 11 Nov 2025 | Quarterly Result Announcement | NA | 11 Nov 2025 | 48.21 | 48.42 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication6 days ago
6 days agoRe-Lodgement Of Requests For Transfer Of Physical Shares7 days ago
7 days ago Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025.8 days ago
8 days agoBoard Meeting Outcome for Outcome Of The Board Meeting8 days ago
8 days agoBoard Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30 2025.Nov 06, 2025
Nov 06, 2025Re-Lodgement Of Requests For Transfer Of Physical SharesOct 15, 2025
Oct 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Oct 08, 2025Closure of Trading WindowSep 30, 2025
Sep 30, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 24, 2025
Sep 24, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 24, 2025
Sep 24, 2025Intimation Under Regulation 31A(10)(Ii) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Reclassification Of Promoter(S) Pursuant To The Open Offer Under SEBI (SAST) Regulations 2011.Sep 24, 2025
Sep 24, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 23, 2025
Sep 23, 2025Announcement under Regulation 30 (LODR)-Diversification / DisinvestmentSep 18, 2025
Sep 18, 2025Announcement Under Regulation 30 - Intimation Of Registration Of Sale Deed.Sep 06, 2025
Sep 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 30, 2025
Aug 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 30, 2025
Aug 30, 2025Reg. 34 (1) Annual Report.Aug 29, 2025
Aug 29, 2025Notice Of Convening The 36Th Annual General MeetingAug 29, 2025
Aug 29, 2025Announcement under Regulation 30 (LODR)-Open Offer - UpdatesAug 29, 2025
Aug 29, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 29, 2025
Aug 29, 2025Post Offer AdvertisementAug 29, 2025
Aug 29, 2025Announcement Under Reg 30(LODR) - Appointment Of Secretarial AuditorAug 21, 2025
Aug 21, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held On August 21 2025.Aug 21, 2025
Aug 21, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Aug 21, 2025
Aug 21, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportAug 18, 2025
Aug 18, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 09, 2025
Aug 09, 2025Announcement under Regulation 30 (LODR)-Resignation of Chief Executive Officer (CEO)Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 07, 2025
Aug 07, 2025Unaudited Financial Results For The Quarter Ended June 30 2025.Aug 07, 2025
Aug 07, 2025Board Meeting Outcome for Outcome Of The Board Meeting Dated August 07 2025.Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Open Offer - UpdatesAug 07, 2025
Aug 07, 2025Updates on Open OfferAug 07, 2025
Aug 07, 2025Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended 30Th June 2025.Aug 04, 2025
Aug 04, 2025Announcement under Regulation 30 (LODR)-Open Offer - UpdatesAug 01, 2025
Aug 01, 2025Updates on Open OfferAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Open Offer - UpdatesJul 30, 2025
Jul 30, 2025Announcement under Regulation 30 (LODR)-Open Offer - UpdatesJul 25, 2025
Jul 25, 2025Letter of OfferJul 25, 2025
Jul 25, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 16, 2025
Jul 16, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 15, 2025
Jul 15, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotJul 14, 2025
Jul 14, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Jul 07, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 04, 2025
Jul 04, 2025Announcement under Regulation 30 (LODR)-Diversification / DisinvestmentJul 04, 2025
Jul 04, 2025Outcome Of The Board MeetingJul 04, 2025
Jul 04, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 24, 2025
May 24, 2025Submission Of Audited Financial Results Along With Auditors Report For The Quarter And Year Ended 31St March 2025May 23, 2025
May 23, 2025Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended March 31St 2025May 23, 2025
May 23, 2025Board Meeting Intimation for Consideration And Approval Of Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended 31St March 2025.May 20, 2025
May 20, 2025Technical Indicators
RSI(14)
Neutral 49.65
ATR(14)
Less Volatile 3.68
STOCH(9,6)
Neutral 37.82
STOCH RSI(14)
Overbought 90.79
MACD(12,26)
Bullish 0.27
ADX(14)
Weak Trend 15.22
UO(9)
Bearish 48.68
ROC(12)
Downtrend But Slowing Down -1.03
WillR(14)
Neutral -33.52
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
